Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

ENGLEWOOD, Colo. , Nov. 1, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common stock.

Zynex Announces Additional Share Buyback Program

The mean of analysts' price targets for Zynex Inc. (ZYXI) points to a 65.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?

Zynex, Inc. (NASDAQ:ZYXI ) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Financial Officer Anna Lucsok – Chief Operating Officer Donald Gregg – Vice President-Zynex Monitoring Solutions Conference Call Participants Simran Kaur – Piper Sandler Jeffrey Cohen – Ladenburg Thalmann Yi Chen – H.C. Wainwright Marc Wiesenberger – B.

Zynex, Inc. (ZYXI) Q3 2022 Earnings Call Transcript

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates

ENGLEWOOD, Colo. , Oct. 27, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the third quarter ended September 30, 2022.

Zynex Announces 2022 Third Quarter Earnings

Canoo

Rush Street Interactive

NuScale Power Corp

SurgePays

Rising interest rates and growing fears of a recession have sent growth stocks plunging in the past year. Yet while some growth names have deservingly moved to lower prices and could keep tumbling, there are many under-the-radar growth stocks that have either become oversold or have seen their performance blunted by investors' poor sentiment.

7 Under-the-Radar Growth Stocks With 200% Growth Potential

ENGLEWOOD, Colo. , Oct. 13, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report third quarter 2022 financial results on Thursday, October 27, 2022.

Zynex, Inc. to Announce Third Quarter 2022 Financial Results

ENGLEWOOD, Colo. , Oct. 11, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for third quarter 2022 and reiterated full year guidance.

Zynex Reports Preliminary Third Quarter 2022 Results

Zynex has succumbed to extensive short selling in 2021-22 that may be in the process of reconsidering bearish bets. Projected growth rates for the company are exceptionally positive, on new product releases.

Short Squeeze Candidate With Low PEG Ratio: Zynex

ENGLEWOOD, Colo. , Sept. 21, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today announced it has begun enrollments in a large-scale blood loss detection clinical trial with its second-generation monitoring system, the CM-1600.

Zynex Monitoring Solutions Announces First Enrollment in a Blood Loss Detection Clinical Trial for its CM-1600 Monitoring System

Aptorum Group Ltd - Ordinary Shares - Class A

vTv Therapeutics

Yatra Online

In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.

7 Hot Small-Cap Stocks to Buy in September

ENGLEWOOD, Colo. , Sept. 1, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate virtually in the H.C.

Zynex Medical to Participate in H.C. Wainwright Annual Global Investment Conference

ENGLEWOOD, Colo. , Aug. 23, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate virtually in the Gilmartin Group Emerging Growth Company Showcase on August 31 st, 2022 at 11:00 am ET.

Zynex Medical to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase

ENGLEWOOD, Colo. , Aug. 15, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has started enrollments in an ongoing apheresis clinical trial with its second-generation fluid monitoring system, the CM-1600.

Zynex Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

ENGLEWOOD, Colo. , Aug. 8, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex as 33rd in the Top 100 Healthcare Technology Companies of 2022.

Zynex Recognized in Top 100 Healthcare Technology Companies of 2022

ENGLEWOOD, Colo. , Aug. 3, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has ranked Zynex number 50 in a list Colorado-based public companies, according to 2021 revenue figures.

Zynex Ranked in Top 50 Public Companies in Colorado

Zynex beat analysts' estimates despite the recession. Zynex is committed to bringing value to its shareholders with a new share buyback round.

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. (NASDAQ:ZYXI ) Q2 2022 Results Conference Call July 28, 2022 4:15 PM ET Company Participants Louisa Smith - Investor Relations-Gilmartin Group Thomas Sandgaard - Chairman, President and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna Lucsok - Chief Operating Officer Don Gregg - Vice President of Zynex Monitoring Solutions Conference Call Participants Simran Kaur - Piper Sandler Jeffrey Cohen - Ladenburg Thalmann Marc Wiesenberger - B. Riley Securities Yi Chen - H.C.

Zynex, Inc. (ZYXI) CEO Thomas Sandgard on Q2 2022 Results - Earnings Call Transcript

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates

ENGLEWOOD, Colo., July 28, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the second quarter ended June 30, 2022.

Zynex Announces 2022 Second Quarter Earnings

ENGLEWOOD, Colo. , July 20, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report second quarter 2022 financial results on Thursday, July 28, 2022.

Zynex, Inc. to Announce Second Quarter 2022 Financial Results

ENGLEWOOD, Colo.  , July 11, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2022 and reiterated full year guidance.

Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance

ENGLEWOOD, Colo. , June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022.

Zynex Announces Change of Auditor

ENGLEWOOD, Colo. , May 10, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it will participate in two upcoming investor conferences.

Zynex Medical to Participate in Upcoming Investor Conferences

ENGLEWOOD, Colo. , May 3, 2022 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, ranked 250 out of 500 on The Financial Times list of Americas' Fastest Growing Companies in 2022.

News for Zynex Inc Stock (ZYXI)